Cannabis, CBD & Athlete Mental Health 2026: Anxiety Evidence

THC's Biphasic Anxiety Dose-Response

THC's effect on anxiety is well-documented as biphasic — meaning the direction of effect depends on dose. Crippa et al. (Journal of Psychopharmacology, 2009) reviewed the human and animal evidence: low doses are anxiolytic; high doses are anxiogenic, with a crossover point that varies between users, contexts, and prior experience.

The practical translation for athletes is consequential. Small doses may reduce competition-related anxiety in some users; larger doses can trigger panic, paranoia, or acute anxiety — particularly in inexperienced users, stressful situations, or unfamiliar settings. The biphasic dose-response is also why anecdotal reports diverge so sharply: athletes who report cannabis as calming and athletes who report it as panic-inducing are usually describing different doses, products, or contexts. The risk is materially higher with high-potency edibles, where dose control is poor and onset is delayed (1-3 hours), making over-consumption likely.

CBD Anxiolysis: 300-600 mg Has the Cleanest Signal Moderate evidence

CBD's anxiolytic signal is the most robust athletic-evidence finding for any cannabinoid. McCartney et al. (Sports Medicine - Open, 2020) reviewed CBD in athletic populations and found that 300-600 mg CBD doses reduced subjective anxiety in stress-inducing contexts — albeit with variable effect sizes across protocols. The supporting evidence base goes back to Bergamaschi et al. (Neuropsychopharmacology, 2011), who tested similar doses in a simulated public-speaking paradigm and found reduced anxiety, cognitive impairment, and discomfort relative to placebo.

The most relevant athlete-population evidence is the Sahinovic et al. randomized trial (JFMK, 2025): 300 mg acute CBD before a 2-mile time trial increased self-reported calm and relaxation and reduced mile-1 rating of perceived exertion (RPE) by approximately 8%, with no measurable performance decrement. This is the cleanest direct evidence that pre-competition CBD can affect the subjective experience of effort without making the athlete slower — a finding that is distinct from "performance enhancement" and consistent with the Doping Authority Netherlands position that cannabinoids are not ergogenic. For the broader CBD evidence audit, see CBD and athletes.

Competition Pressure and the Anxiety-Performance Curve

Sport psychology has long recognized the inverted-U relationship between arousal and performance (Yerkes-Dodson): too little arousal under-mobilizes; too much arousal — particularly in skill-dependent or fine-motor tasks — degrades performance through tremor, narrowed attention, and motor disinhibition. The therapeutic target for anxiolytic interventions is the high-arousal end of that curve: athletes who routinely over-arouse, panic-grade competitors, those new to a level of competition, or those returning from injury.

CBD anxiolysis in this frame is not "calm everyone down" but "trim the high end of the arousal distribution for athletes who over-mobilize." The Sahinovic 300 mg-before-2-mile finding is consistent with that frame: subjective experience of effort improved, performance held. Whether and how athletes integrate this into competition prep is a personal-medicine question that depends on how their nerves typically affect them, what testing regime they operate under (CBD is permitted by WADA but contamination remains a risk — see contamination risk), and whether their league context permits it (it does for the NBA, MLB, NWSL, NCAA D-I postseason, and the post-CSAD UFC).

Post-Career Mental Health and the Athletes for CARE Coalition

The mental-health stakes for elite athletes do not end at retirement. CTE, chronic pain from accumulated injuries, identity loss, financial instability, and substance-use disorders — particularly opioid dependence acquired through pain-management chains during playing careers — combine to make the post-career window a documented high-risk period. Cannabis policy reform in pro sports has been driven in significant part by retired-athlete advocacy.

Athletes for CARE — founded in 2017 by Eugene Monroe, Marvin Washington, Riley Cote, and Cliff Robinson — is the principal athlete-led coalition advocating for cannabis as a safer alternative to opioids and for broader mental-health support for retired athletes. Eugene Monroe's May 23, 2016 Players' Tribune op-ed "Getting Off the T Train" was the first by an active NFL player to publicly call for the league to remove cannabis from testing and address opioid dependence. For the full advocacy-organization landscape, see advocacy & orgs.

NFL Joint Pain Management Committee Research

The most consequential institutional research investment in athlete cannabis-and-mental-health science to date is the NFL Joint Pain Management Committee (PMC), co-chaired by Dr. Kevin Hill (Director of Addiction Psychiatry at Beth Israel Deaconess; Associate Professor at Harvard Medical School) and on the NFLPA side by Dr. Thom Mayer. The PMC issued a 2021 RFP that drew 106 submissions. On February 1, 2022, the NFL announced $1 million in awards split between two teams:

• UC San Diego's Center for Medicinal Cannabis Research (Drs. Mark Wallace and Thomas Marcotte, co-PIs), studying vaporized 4% THC, 12% CBD, combined THC/CBD, and placebo for "relief of post-competition soft-tissue injury pain in elite athletes." Because the NFL CBA constrains active-player participation, the trial uses rugby-player participants.
• University of Regina (Dr. Patrick Neary), studying cannabinoids for concussion neuroprotection.

A second round announced in 2023 funded ASPN (CBD plus non-invasive vagal nerve stimulation for concussion) and Emory University for mindfulness-based interventions in athlete mental health. The Emory mindfulness award is notable as a structural acknowledgment by the league that mental-health interventions in athletes do not all need to be pharmacologic. See NFL cannabis policy for the broader CBA context.

Practical Take for Athlete Mental Health

• If competition anxiety is the target: CBD at 300-600 mg pre-event has the cleanest evidence; expect subjective effects more than objective performance changes.
• If the goal is to use THC pre-competition for nerves: the biphasic dose-response, plus the cardiac and reaction-time costs covered on THC and athletic performance, make this a poor strategy compared to either CBD or non-pharmacological interventions.
• If you operate under WADA, MLS, WNBA, or NFL testing: verify CBD product purity via NSF Certified for Sport; THC contamination is the documented inadvertent-positive route.
• For broader athlete mental-health support: Athletes for CARE, USADA Athlete Express, NFLPA "The Trust," NBPA Mental Health & Wellness Program, and SAMHSA 1-800-662-HELP are first-line resources — see helplines and clinicians.